NCT06488105RecruitingPhase 2
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- First submitted
- 28 Jun 2024
- Start date
- 5 Aug 2024
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT06488105
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 130
- From 5 Aug 2024 to the primary completion date, 30 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran, etc.)
Other illness
- ST-Segment Elevation Myocardial Infarction (STEMI) Activation
Lab values
- End-stage renal disease (ESRD) and/or glomerular filtration rate (GFR) \<30 mL/min/1.73 m2
Other
- ST Depression \>1 mm in Contiguous Leads
- Inability to Return for 30-day Follow-up
- Unstable Vitals (Systolic blood pressure \<90, HR \>120 or \<50, oxygen saturation \<90%)
- Statin Intolerance
- Any Resulted High-Sensitivity Troponin I ≥100 ng/L
- Liver Cirrhosis
- Pregnancy
- Anticipated Hospitalization
- Life Expectancy \<1 Year
- Transfer from Another Hospital
- Prisoner
- Non-English Speaking
Who the study is looking for
- Evaluation for Acute Coronary Syndrome
- Age 40-75 Years
- 10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk ≥7.5% or Known Diabetes or
- Known ASCVD:
- Myocardial Infarction
- Unstable Angina
- Percutaneous Coronary Intervention
- Coronary Artery Bypass Graft
- Stroke
- Transient Ischemic Attack
- Peripheral Artery Disease
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wake Forest University Health Sciences Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.